Alirocumab
Alirocumab
Definition
A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia. Upon administration, alirocumab targets, binds to and inhibits the activity of PCSK9. This prevents the binding of PCSK9 to low-density lipoprotein receptor (LDLR) on hepatocytes and prevents its degradation. This increases LDLR on hepatocytes and increases the liver's ability to remove LDL cholesterol (LDL-C) from the blood, thereby lowering LDL-C levels. PCSK9 binds to LDLR on the surface of hepatocytes to promote LDLR degradation within the liver.
Also known as ALIROCUMAB, Praluent — per NCIT
Also identified as
- ATC C10AX14 per RXNORM
- NCIT NCIT:C174849 per NCIT
- SCTID 715186005 per RXNORM
- SCTID 781355008 per RXNORM
- UNII PP0SHH6V16 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Atherosclerosis | may prevent | MEDRT · Public domain (U.S. Government work) |
| Myocardial infarction | may prevent | MEDRT · Public domain (U.S. Government work) |
| Atherosclerosis | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Artery | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Cardiovascular system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.